1.Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
Choong-kun LEE ; Jeong Min CHOO ; Yong Chan AHN ; Jin KIM ; Sun Young RHA ; Chai Hong RIM ;
Cancer Research and Treatment 2025;57(1):11-18
During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.
2.Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
Choong-kun LEE ; Jeong Min CHOO ; Yong Chan AHN ; Jin KIM ; Sun Young RHA ; Chai Hong RIM ;
Cancer Research and Treatment 2025;57(1):11-18
During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.
3.Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
Choong-kun LEE ; Jeong Min CHOO ; Yong Chan AHN ; Jin KIM ; Sun Young RHA ; Chai Hong RIM ;
Cancer Research and Treatment 2025;57(1):11-18
During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.
4.Singapore consensus statements on the management of obstructive sleep apnoea.
Leong Chai LEOW ; Chuen Peng LEE ; Sridhar VENKATESWARAN ; Michael Teik Chung LIM ; Oon Hoe TEOH ; Ruth CHANG ; Yam Cheng CHEE ; Khai Beng CHONG ; Ai Ping CHUA ; Joshua GOOLEY ; Hong Juan HAN ; Nur Izzianie KAMARUDDIN ; See Meng KHOO ; Lynn Huiting KOH ; Shaun Ray Han LOH ; Kok Weng LYE ; Mark IGNATIUS ; Yingjuan MOK ; Jing Hao NG ; Thun How ONG ; Chu Qin PHUA ; Rui Ya SOH ; Pei Rong SONG ; Adeline TAN ; Alvin TAN ; Terry TAN ; Jenny TANG ; David TAY ; Jade TAY ; Song Tar TOH ; Serene WONG ; Chiang Yin WONG ; Mimi YOW
Annals of the Academy of Medicine, Singapore 2025;54(10):627-643
INTRODUCTION:
Obstructive sleep apnoea (OSA) is common in Singapore, with moderate to severe OSA affecting around 30% of residents. These consensus statements aim to provide scientifically grounded recommendations for the management of OSA, standar-dise the management of OSA in Singapore and promote multidisciplinary collaboration.
METHOD:
An expert panel, which was convened in 2024, identified several areas of OSA management that require guidance. The expert panel reviewed the current literature and developed consensus statements, which were later independently voted on using a 3-point Likert scale (agree, neutral or disagree). Consensus (total ratings of agree and neutral) was set a priori at ≥80% agreement. Any statement not reaching consensus was excluded.
RESULTS:
The final consensus included 49 statements that provide guidance on the screening, diagnosis and management of adults with OSA. Additionally, 23 statements on the screening, diagnosis and management of paediatric OSA achieved consensus. These 72 consensus statements considered not only the latest clinical evidence but also the benefits and harms, resource implications, feasibility, acceptability and equity impact of the recommendations.
CONCLUSION
The statements presented in this paper aim to guide clinicians based on the most updated evidence and collective expert opinion from sleep specialists in Singapore. These recommendations should augment clinical judgement rather than replace it. Management decisions should be individualised, taking into account the patient's clinical characteristics, as well as patient and caregiver concerns and preferences.
Humans
;
Sleep Apnea, Obstructive/diagnosis*
;
Singapore
;
Consensus
;
Adult
5.Effect of LINC00641 on Viability and Apoptosis of Acute Myeloid Leukemia Cells.
Yun-Ling ZHANG ; Ying YANG ; Yin SUN ; Hong-Li CHAI
Journal of Experimental Hematology 2025;33(4):998-1006
OBJECTIVE:
To investigate the effect of LINC00641 on the viability and apoptosis of acute myeloid leukemia (AML) cells and its mechanism.
METHODS:
RT-qPCR was applied to detect the relative expression levels of LINC00641, miR-204-5p, and MT1X in human normal bone marrow stromal cell lines HS-5 and AML cell lines, and to screen the optimal cell line THP-1 was screened for subsequent experiments. Bioinformatics, dual luciferase reporter assay, pull down assay, and RIP assay were applied to validate the targeting relationship between LINC00641, MT1X and miR-204-5p. EdU, CCK-8, flow cytometry, and Transwell assay were applied to detect cell proliferation, apoptosis, migration and invasion, respectively. Western blot was applied to detect the expression of MT1X , CyclinD1, Bcl-2, and Bax proteins.
RESULTS:
Compared with HS-5 cells, the expression of LINC00641 and MT1X was obviously increased in HL60, THP-1, U937, and KG1 cells, while the expression of miR-204-5p was obviously reduced (all P <0.05). THP-1 cells showed the most obvious changes (P <0.05). Silencing LINC00641 or overexpressing miR-204-5p was able to obviously inhibit the proliferation, migration and invasion of THP-1 cells, as well as the expression of CyclinD1 and Bcl-2 proteins, while promote cells apoptosis and Bax protein expression (all P <0.05). Bioinformatics analysis, dual luciferase reporter assay, pull down assay, and RIP assay all confirmed that there were targeted relationships between LINC00641, MT1X and miR-204-5p. Inhibiting miR-204-5p or overexpressing MT1X was able to respectively reverse the inhibitory effect of silencing LINC00641 or overexpressing miR-204-5p on THP-1 cells proliferation, migration and invasion, and reduce cells apoptosis.
CONCLUSION
LINC00641 is highly expressed in AML, and inhibition of LINC00641 expression can inhibit cell proliferation, migration, and invasion and increase apoptosis by regulating the miR-204-5p/MT1X axis.
Humans
;
Apoptosis
;
Leukemia, Myeloid, Acute/pathology*
;
MicroRNAs
;
Cell Proliferation
;
RNA, Long Noncoding/genetics*
;
Cell Movement
;
Cell Survival
;
Cell Line, Tumor
;
HL-60 Cells
6.Application Status of Machine Learning in Assisted Diagnosis Techniques of Cardiovascular Diseases.
Pinliang LIAO ; Zihong WANG ; Miao TIAN ; Hong CHAI ; Xiaoyu CHEN
Chinese Journal of Medical Instrumentation 2025;49(1):24-34
In recent years, cardiovascular disease has become a common disease. With the development of machine learning and big data technologies, the processing ability of electrocardiogram (ECG) signals has been greatly enhanced through new computer technologies, enabling the auxiliary diagnosis technology for cardiovascular disease (CVD) to achieve new improvements. This article discusses the application of machine learning in ECG processing, especially in the auxiliary diagnosis of diseases. Firstly, the conventional signal preprocessing methods are introduced, and then the EEG signal processing methods based on feature extraction and fuzzy classification are explored. Secondly, the application of auxiliary diagnosis in CVD is further summarized. Finally, the advantages and disadvantages of the two methods are analyzed, and based on this, a design of an auxiliary diagnostic system compatible with the two methods is proposed, providing a new perspective for similar applied researches in the future.
Machine Learning
;
Cardiovascular Diseases/diagnosis*
;
Humans
;
Electrocardiography
;
Signal Processing, Computer-Assisted
;
Diagnosis, Computer-Assisted
;
Fuzzy Logic
;
Electroencephalography
7.Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study.
Zhao ZHANG ; Hua JIANG ; Li HUANG ; Sixi LIU ; Xiaoya ZHOU ; Yun CAI ; Ming LI ; Fei GAO ; Xiaoting LIANG ; Kam-Sze TSANG ; Guangfu CHEN ; Chui-Yan MA ; Yuet-Hung CHAI ; Hongsheng LIU ; Chen YANG ; Mo YANG ; Xiaoling ZHANG ; Shuo HAN ; Xin DU ; Ling CHEN ; Wuh-Liang HWU ; Jiacai ZHUO ; Qizhou LIAN
Protein & Cell 2025;16(1):16-27
Metachromatic leukodystrophy (MLD) is an inherited disease caused by a deficiency of the enzyme arylsulfatase A (ARSA). Lentivirus-modified autologous hematopoietic stem cell gene therapy (HSCGT) has recently been approved for clinical use in pre and early symptomatic children with MLD to increase ARSA activity. Unfortunately, this advanced therapy is not available for most patients with MLD who have progressed to more advanced symptomatic stages at diagnosis. Patients with late-onset juvenile MLD typically present with a slower neurological progression of symptoms and represent a significant burden to the economy and healthcare system, whereas those with early onset infantile MLD die within a few years of symptom onset. We conducted a pilot study to determine the safety and benefit of HSCGT in patients with postsymptomatic juvenile MLD and report preliminary results. The safety profile of HSCGT was favorable in this long-term follow-up over 9 years. The most common adverse events (AEs) within 2 months of HSCGT were related to busulfan conditioning, and all AEs resolved. No HSCGT-related AEs and no evidence of distorted hematopoietic differentiation during long-term follow-up for up to 9.6 years. Importantly, to date, patients have maintained remarkably improved ARSA activity with a stable disease state, including increased Functional Independence Measure (FIM) score and decreased magnetic resonance imaging (MRI) lesion score. This long-term follow-up pilot study suggests that HSCGT is safe and provides clinical benefit to patients with postsymptomatic juvenile MLD.
Humans
;
Leukodystrophy, Metachromatic/genetics*
;
Pilot Projects
;
Genetic Therapy/methods*
;
Hematopoietic Stem Cell Transplantation
;
Male
;
Follow-Up Studies
;
Female
;
Lentivirus/genetics*
;
Child
;
Child, Preschool
;
Hematopoietic Stem Cells/metabolism*
;
Cerebroside-Sulfatase/metabolism*
;
Adolescent
8.Analysis of inorganic elements in different batches of earthworm polypeptides by ICP-MS combined with chemometrics technology
Hong-liu YANG ; Wei-ting ZHONG ; Yu-shi GUO ; Shu-qi LI ; Jin-chai QI ; Yong-gang LIU ; Tao MA
Acta Pharmaceutica Sinica 2024;59(4):1040-1047
To establish a method for determining 26 inorganic elements in earthworm polypeptide and determine the elemental content in different batches of earthworm polypeptide, microwave digestion method was used to pre-treat the samples, and ICP-MS method was used to determine the content of 26 elements in different batches of earthworm polypeptide. The linear relationships of 26 elements were good in the range of 0-1 000 μg·L-1, with
9.Study on the material basis and mechanism of anti-insomnia mechanism of Ning Shen Essential Oil based on 1H NMR metabolomics and network pharmacology
Qing CHAI ; Hong-bin ZHANG ; Li-dong WU ; Jing-yi WANG ; Hai-chao LI ; Yu-hong LIU ; Hong-yan LIU ; Hai-qiang JIANG ; Zhen-hua TIAN
Acta Pharmaceutica Sinica 2024;59(8):2313-2325
This paper applied gas chromatography-mass spectrometry (GC-MS), network pharmacology and nuclear magnetic resonance hydrogen spectroscopy (1H NMR) metabolomics techniques to study the material basis and mechanism of action of Ning Shen Essential Oil in anti-insomnia. The main volatile components of Ning Shen Essential Oil were analyzed by gas chromatography-mass spectrometry (GC-MS), and the insomnia-related targets were predicted using the Traditional Chinese Medicine Systematic Pharmacology Database and Analytical Platform (TCMSP) and the databases of GeneCards, OMIM and Drugbank. The insomnia model of rats was replicated by intraperitoneal injection of 4-chloro-
10.Study on recombinant adenovirus vector vaccine in G protein conserved domain of respiratory syncytial virus
Yi SHI ; Pengdi CHAI ; Zhaojun DUAN ; Qing ZHANG ; Xiangyu KONG ; Hong WANG ; Lili PANG ; Dandi LI
Chinese Journal of Experimental and Clinical Virology 2024;38(5):497-505
Objective:A recombinant adenoviral vector vaccine based on non-replicating human adenovirus type 5 (Ad5), encoding the conserved domain of respiratory syncytial virus G protein (RSV-G) was constructed. The immunogenicity and protective efficacy of this vaccine were subsequently evaluated in mice.Methods:The recombinant Ad5 vector plasmid (Ad5-Gbcc-Gacc) was constructed by inserted conserved domains of RSV A and RSV B. The recombinant adenovirus Ad5-Gbcc-Gacc was rescued in HEK293A cells. The genome of virus Ad5-Gbcc-Gacc was identified by multi-enzyme digestion, and the expression of Ad5-Gbcc-Gacc was verified by Western blot. Recombinant adenovirus was used to immunize BALB/c mice via intramuscular injection with signal dose, and then challenged with RSV Long strain at week 6. The levels of G specific IgG and antibody subtypes in serum were detected by enzyme-linked immunosorbent assay, the level of neutralizing antibodies was determined by micro-neutralization assay. After challenge, the mice′s weight was recorded daily, the copies of RSV virus in the lung and nasal tissues were detected. Pathological changes in lung tissue were also examined.Results:Western blot and multi-enzyme digestion identification confirmed the successful rescue of the recombinant adenovirus. Ad5-Gbcc-Gacc elicit high titers of specific IgG, robust neutralizing antibodies, and a balanced Th1/Th2 immune response in mice. In comparison to unimmunized controls, mice immunized with Ad5-Gbcc-Gacc reduced the viral copies in both lung and nasal tissue, and exhibited only minimal pathological damage of lung tissue following RSV challenge. In conclusion, Ad5-Gbcc-Gacc induced robust immunogenicity and offers protective effects against RSV infection in murine models.Conclusions:Ad5-Gbcc-Gacc induce robust immunogenicity and can protect mice from RSV challenge, which lays a foundation for further development of RSV vaccine based on G protein.

Result Analysis
Print
Save
E-mail